Postdischarge antibiotic use for prophylaxis following spinal fusion.


Journal

Infection control and hospital epidemiology
ISSN: 1559-6834
Titre abrégé: Infect Control Hosp Epidemiol
Pays: United States
ID NLM: 8804099

Informations de publication

Date de publication:
07 2020
Historique:
pubmed: 6 5 2020
medline: 18 8 2021
entrez: 6 5 2020
Statut: ppublish

Résumé

Despite recommendations to discontinue prophylactic antibiotics after incision closure or <24 hours after surgery, prophylactic antibiotics are continued after discharge by some clinicians. The objective of this study was to determine the prevalence and factors associated with postdischarge prophylactic antibiotic use after spinal fusion. Multicenter retrospective cohort study. This study included patients aged ≥18 years undergoing spinal fusion or refusion between July 2011 and June 2015 at 3 sites. Patients with an infection during the surgical admission were excluded. Prophylactic antibiotics were identified at discharge. Factors associated with postdischarge prophylactic antibiotic use were identified using hierarchical generalized linear models. In total, 8,652 spinal fusion admissions were included. Antibiotics were prescribed at discharge in 289 admissions (3.3%). The most commonly prescribed antibiotics were trimethoprim/sulfamethoxazole (22.1%), cephalexin (18.8%), and ciprofloxacin (17.1%). Adjusted for study site, significant factors associated with prophylactic discharge antibiotics included American Society of Anesthesiologists (ASA) class ≥3 (odds ratio [OR], 1.31; 95% CI, 1.00-1.70), lymphoma (OR, 2.57; 95% CI, 1.11-5.98), solid tumor (OR, 3.63; 95% CI, 1.62-8.14), morbid obesity (OR, 1.64; 95% CI, 1.09-2.47), paralysis (OR, 2.38; 95% CI, 1.30-4.37), hematoma/seroma (OR, 2.93; 95% CI, 1.17-7.33), thoracic surgery (OR, 1.39; 95% CI, 1.01-1.93), longer length of stay, and intraoperative antibiotics. Postdischarge prophylactic antibiotics were uncommon after spinal fusion. Patient and perioperative factors were associated with continuation of prophylactic antibiotics after hospital discharge.

Identifiants

pubmed: 32366333
pii: S0899823X20001178
doi: 10.1017/ice.2020.117
pmc: PMC7641990
mid: NIHMS1613092
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article Multicenter Study Research Support, N.I.H., Extramural Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

789-798

Subventions

Organisme : NCI NIH HHS
ID : P30 CA091842
Pays : United States
Organisme : ACL HHS
ID : U54CK000482
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000448
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002345
Pays : United States

Références

Spine (Phila Pa 1976). 2008 Nov 15;33(24):2651-61; discussion 2662
pubmed: 18981957
Surg Neurol. 2008 Dec;70(6):622-7; discussion 627
pubmed: 18207532
Asian Spine J. 2010 Dec;4(2):71-6
pubmed: 21165308
J Bone Joint Surg Am. 2018 Dec 19;100(24):2103-2109
pubmed: 30562290
Spine (Phila Pa 1976). 2009 Aug 1;34(17):1869-72
pubmed: 19644339
Infect Control Hosp Epidemiol. 2017 Oct;38(10):1254-1257
pubmed: 28756789
Asian Spine J. 2016 Dec;10(6):1018-1022
pubmed: 27994776
J Neurosurg. 2003 Mar;98(2 Suppl):149-55
pubmed: 12650399
J Bone Joint Surg Am. 2012 Aug 1;94(15):1359-66
pubmed: 22740029
Med Care. 1998 Jan;36(1):8-27
pubmed: 9431328
J Am Coll Surg. 2010 Dec;211(6):705-14
pubmed: 21109157
Am J Infect Control. 2015 Jan;43(1):44-7
pubmed: 25564123
Spine J. 2013 Oct;13(10):1387-92
pubmed: 23988461
J Hosp Infect. 2019 Nov;103(3):303-310
pubmed: 31051190
J Bone Joint Surg Am. 2012 Feb 15;94(4):335-42
pubmed: 22336972
PLoS One. 2017 Jun 16;12(6):e0179117
pubmed: 28622340
Spine (Phila Pa 1976). 2012 Nov 15;37(24):2017-33
pubmed: 22565388
Rev Bras Ortop. 2016 May 02;51(3):333-6
pubmed: 27274488
Spine (Phila Pa 1976). 2020 Feb 1;45(3):208-216
pubmed: 31464972
Spine (Phila Pa 1976). 2003 Jul 1;28(13):1475-80
pubmed: 12838110
Circulation. 2000 Jun 27;101(25):2916-21
pubmed: 10869263
Eur Spine J. 2018 Oct;27(10):2469-2480
pubmed: 30128761
J Bone Joint Surg Am. 2015 Jun 17;97(12):979-86
pubmed: 26085531
JAMA Surg. 2019 Jul 1;154(7):590-598
pubmed: 31017647
J Orthop Sci. 2010 May;15(3):305-9
pubmed: 20559797
J Thorac Cardiovasc Surg. 2016 Feb;151(2):589-97.e2
pubmed: 26545971
JAMA Surg. 2017 Aug 1;152(8):784-791
pubmed: 28467526
Eur Spine J. 2016 Oct;25(10):3242-3248
pubmed: 26971263
N Engl J Med. 2018 Nov 1;379(18):1732-1744
pubmed: 30380384
Surg Infect (Larchmt). 2016 Dec;17(6):625-631
pubmed: 27828764

Auteurs

David K Warren (DK)

Division of Infectious Diseases, Washington University School of Medicine, St Louis, Missouri.

Katelin B Nickel (KB)

Division of Infectious Diseases, Washington University School of Medicine, St Louis, Missouri.

Jennifer H Han (JH)

Division of Infectious Diseases, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

Pam Tolomeo (P)

Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

Christopher J Hostler (CJ)

Duke Center for Antimicrobial Stewardship and Infection Prevention, Duke University School of Medicine, Durham, North Carolina.
Infectious Diseases Section, Durham VA Health Care System, Durham, North Carolina.

Katherine Foy (K)

Duke Center for Antimicrobial Stewardship and Infection Prevention, Duke University School of Medicine, Durham, North Carolina.

Ian R Banks (IR)

Division of Infectious Diseases, Washington University School of Medicine, St Louis, Missouri.

Victoria J Fraser (VJ)

Division of Infectious Diseases, Washington University School of Medicine, St Louis, Missouri.

Margaret A Olsen (MA)

Division of Infectious Diseases, Washington University School of Medicine, St Louis, Missouri.
Division of Public Health Sciences, Washington University School of Medicine, St Louis, Missouri (Present affiliation: GlaxoSmithKline, Rockville, MD [J.H.H.].).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH